Tevogen Bio
Ejecutivos
Ver el organigrama con sus 16 ejecutivos principales
Biografías más buscadas en Tevogen Bio
- Ryan Saadi, Chairman of the Board and Chief Executive Officer
- Lindee Goh, Director
- Curtis Patton, Director
Recientes movimientos de ejecutivos en Tevogen Bio
- Tapan Shah, se ha incorporado a la empresa como Head of Investor Relations and Corporate Development (noticia publicada el 5 de abril de 2024).
- Mittul Mehta, se ha incorporado a la empresa como Chief Information Officer and Head of Tevogen.ai (noticia publicada el 24 de octubre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Tevogen Bio.
Biotecnología
Tevogen Bio tiene 2.295 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Johnson & Johnson has announced the acquisition of Proteologix (publicado el 20 de mayo de 2024).
- Rapport Therapeutics acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 20 de mayo de 2024).
- Lycia Therapeutics acaba de anunciar una recaudación de fondos de 107 millones de dólares. (publicado el 15 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Tevogen Bio
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Reports Series A-1 Preferred Stock Investment
- Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
- Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
- Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus
- Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
- Tevogen Bio Announces $8 Million Equity Investment
- Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
- View more press releases Close
Redes sociales sobre Tevogen Bio
- Tevogen Bio en Wikipedia, Google News y Yahoo Finance
- Tevogen Bio en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Ryan Saadi 
Llame a Tevogen Bio al +1 267...
